Drug Profile
Research programme: metabolic disorder therapeutics - HemoShear Therapeutics
Latest Information Update: 28 Dec 2023
Price :
$50
*
At a glance
- Originator HemoShear
- Developer Childrens National Health System; HemoShear Therapeutics
- Class Anti-inflammatories; Hepatoprotectants
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- No development reported Methylmalonic acidaemia; Non-alcoholic steatohepatitis; Propionic acidaemia
Most Recent Events
- 28 Dec 2023 No recent reports of development identified for preclinical development in Methylmalonic-acidaemia in USA
- 28 Dec 2023 No recent reports of development identified for preclinical development in Propionic-acidaemia in USA
- 28 Nov 2021 No recent reports of development identified for research development in Non-alcoholic-steatohepatitis in USA